WO2014117700A1 - 一种原人参二醇衍生物、其制备方法及其应用 - Google Patents
一种原人参二醇衍生物、其制备方法及其应用 Download PDFInfo
- Publication number
- WO2014117700A1 WO2014117700A1 PCT/CN2014/071500 CN2014071500W WO2014117700A1 WO 2014117700 A1 WO2014117700 A1 WO 2014117700A1 CN 2014071500 W CN2014071500 W CN 2014071500W WO 2014117700 A1 WO2014117700 A1 WO 2014117700A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- derivative
- noh
- protopanaxadiol
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Definitions
- the present invention relates to a ginseng glycol compound, and more particularly to a protopanaxadiol derivative, a preparation method thereof and application in the field of medicine; and belongs to the field of medical technology. Background technique
- Depression is a disease characterized by depression and depression. In mental illness, it is a category of affective disorder.
- the performance of depression can be summarized as "three lows", that is, low mood, slow thinking and depression.
- the core symptoms are depression, psychological symptoms such as anxiety, self-blame, revoke, illusion, loss of attention and memory, suicidal tendencies, etc.; physical symptoms are sleep disorder, loss of appetite, weight loss, loss of libido, god Tired and so on.
- Depression is a common and frequently-occurring disease that endangers human health. In China, the incidence of affective psychosis is 0.76%. The incidence of depression is high, but the cause of its onset is still not very clear.
- the pathogenesis of depression is associated with abnormalities in monoamine neurotransmitters in the brain, including 5-hydroxytryptamine, acetylcholine, and catecholamines, norepinephrine and epinephrine.
- the first antidepressant developed was a monoamine oxidase inhibitor, which was replaced by a tricyclic antidepressant due to severe toxic side effects, which became the first line of treatment for depression worldwide in the 1950s and 1980s.
- the selective serotonin reuptake inhibitor (SSRI) has attracted remarkable attention in recent years. It has good pharmacokinetic and pharmacodynamic characteristics, and has good efficacy, low toxicity and side effects, and is easy to take and develops rapidly. Most of these drugs have their own characteristics, but they have certain side effects in the central nervous system and autonomic nervous system, and are accompanied by gastrointestinal reactions.
- 20 (S) - Protopanaxadiol is one of the important aglycones of diol group ginsenosides, and ZL 200610027507.1 discloses the use of 20(S)-protopanaxadiol in antidepressant.
- the effect needs to be improved. If an improved and unique structure of the original ginseng diol derivative can be developed, it has a stronger antidepressant pharmacological activity in the pharmacological test results. It will have broad development and application prospects in the prevention or treatment of depressive mental illness. Summary of the invention
- the present invention provides a protopanaxadiol derivative having the formula I or oxime, which has the structural formula:
- R 2 is not -OH.
- R 2 NOH or -NH 2
- R 1 NOH or -NH 2 .
- RPR 2 is simultaneously or not simultaneously NOH or -NH 2 .
- the protopanaxadiol derivative of the formula I or hydrazine of the present invention is prepared by the following method:
- step 2) then adding the mono- or di-oxidative derivative obtained in step 1) with hydroxylamine hydrochloride
- the reaction is carried out, or a further reduction reaction is carried out to obtain a compound represented by the formula (I) or (II).
- the oxidizing agent used in the oxidation in the step 1) is manganese dioxide, potassium permanganate,
- Dess-Martin Dies-Martin reagent
- PCC pyridine chlorochromate
- PDC chlorine dichromate pyridine
- Jones reagent Jones reagent
- the reducing agent used in the reduction reaction in the step 2) is NaBH 4 , LiAlH 4 ,
- One or more of Na/n-propanol, Zn/AcOH reagents are provided.
- the protopanaxadiol derivative of the structural formula I or II of the present invention has stronger antidepressant activity than the original panaxadiol and can be used as an active ingredient of an antidepressant.
- the present invention relates to the use of a protopanaxadiol derivative having the compound I and the compound oxime structure for the preparation of a medicament for preventing or treating depressive psychosis.
- the depressive psychosis includes depressive episodes and recurrent depressive disorder, two-way emotional disorder Impediment and persistent mood disorders.
- the symptoms of the depressive psychiatric disorder are classified into three types: mild, moderate, and severe.
- One or more of the protopanaxadiol derivatives selected from the structural formula I or II are used as active ingredients, and a pharmaceutical preparation is prepared in accordance with a conventional method in the pharmaceutical field with one or more pharmaceutically acceptable carriers.
- the pharmaceutical preparation may be any preparation in the art, such as an oral preparation or an injection.
- the oral agent is a capsule, tablet, pill or granule. It is preferably a capsule.
- the content of the active ingredient protopanaxadiol derivative in the pharmaceutical preparation can be determined in accordance with the amount used.
- the carrier includes conventional stabilizers, fillers, binders, lubricants, disintegrants, absorption enhancers, surfactants, suspending agents, wetting agents, solvents or flavoring agents and the like in the pharmaceutical field.
- the stabilizer is selected from the group consisting of parabens such as methylparaben, methylparaben or hydroxypropylpropyl ester; alcohols such as chlorobutanol, benzyl alcohol or phenylethyl alcohol; benzalkonium chloride; phenol or cresol And other phenols; thimerosal; acetic anhydride; or sorbic acid.
- parabens such as methylparaben, methylparaben or hydroxypropylpropyl ester
- alcohols such as chlorobutanol, benzyl alcohol or phenylethyl alcohol
- benzalkonium chloride phenol or cresol And other phenols
- thimerosal acetic anhydride
- sorbic acid sorbic acid
- the filler is selected from the group consisting of starch, sucrose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose or glucose;
- the binder is selected from the group consisting of cellulose derivatives, alginates, gelatin or polyvinylpyrrolidone;
- the lubricant is selected from the group consisting of stearic acid, polyethylene glycol, calcium carbonate, sodium hydrogencarbonate, micronized silica gel, talc or magnesium stearate;
- the disintegrant is selected from the group consisting of microcrystalline cellulose, sodium carboxymethyl starch, crosslinked polyvinylpyrrolidone, low substituted hydroxypropyl cellulose or croscarmellose sodium;
- the surfactant is selected from the group consisting of sodium dodecylbenzenesulfonate, stearic acid, polyoxyethylene-polyoxypropylene copolymer, fatty acid sorbitan or polysorbate (Tween);
- the suspending agent is selected from the group consisting of micronized silica gel, beeswax, cellulose or solid polyethylene glycol; and the wetting agent is selected from the group consisting of glycerin, Tween-80, ethoxylated hydrogenated castor oil or lecithin;
- the solvent is selected from the group consisting of ethanol, liquid polyethylene glycol, isopropanol, Tween-80, glycerin, propylene glycol or vegetable oil, and the vegetable oil is selected from the group consisting of soybean oil, castor oil, peanut oil or blended oil;
- the flavoring agent is selected from the group consisting of aspartame, sucralose, flavor, citric acid or saccharin.
- the present invention also relates to the use of a pharmaceutical preparation comprising a protopanaxadiol derivative having the above structural formula I or oxime for the preparation of a medicament for preventing or treating a depressive psychiatric disease.
- the depressive psychosis includes depressive episodes and recurrent depressive disorder, two-way emotional disorders, and persistent mood disorders.
- the symptoms of the depressive psychiatric disorder are classified into three types: mild, moderate, and severe.
- the pharmacological experimental study of the present invention shows that the protopanaxadiol derivative of structural formula I or II can significantly shorten the time of mouse tail suspension in the classic model of depression - "tail tail suspension test"; The swimming model test can significantly shorten the swimming time of the mice; in the CUMS test, the sucrose intake of the rats is significantly increased. It is shown that the protopanaxadiol derivative of the present invention has significant antidepressant activity and has potential medicinal value for the treatment of antidepressant psychotic diseases.
- the present invention has structurally modified the original ginseng diol to obtain a variety of novel, structurally unique compounds, and it has been confirmed by in vivo pharmacological experiments that these compounds are expressed at lower doses than the positive control drugs. It has stronger antidepressant activity and can be used as an active ingredient in the preparation of a medicament for preventing or treating depressive psychotic diseases, and has wide application and development prospects.
- 1 to 8 are the effects of the original ginseng diol derivative of Experimental Example 1 on the forced swimming test in mice; wherein: 1 : blank solvent group; 2: venlafaxine group (32 mg/kg); 3: Protopanaxadiol group (0.75 mg/kg); 4: Example 1-8 (0.15 mg/kg); 5: Example 1-8 (0.375 mg/kg); 6: Example 1-8 (0.75 mg) /kg); 7: Example 1-8 (1.5 mg/kg); 8: Example 1-8 (3 mg/kg); *P ⁇ 0.05, **P ⁇ 0.01 compared with the blank solvent group; 9-16 are the effects of the original ginseng diol derivative of Experimental Example 2 on the tail suspension test of the mouse; wherein: 1 : blank solvent group; 2: venlafaxine group (32 mg/kg); 3: original Panaxadiol group (0.75 mg/kg); 4: Example 1-8 (0.15 mg/kg); 5: Example 1-8 (0.375 mg/kg); 6: Example 1-8 (0.75 mg/
- the materials used in the present invention are all conventional materials which can be purchased from the market, and the unmentioned operation methods are also conventional methods in the art.
- Protopanaxadiol derivative of formula of formula (II) ( ⁇ is -011, R 2 is -NH 2)
- lOg compound I any one of the compounds I obtained in the above Examples 1-4, 9 and 10
- Compound I any of the compounds I obtained in the above Examples 1 to 4, 9 and 10
- an appropriate amount of lactose mixed, 70% ethanol as a binder, granulated, dried, added Appropriate amount of magnesium stearate, tablet, that is, tablets, each containing 50 mg of compound I.
- mice All mice were unscreened and randomized, according to the drugs and doses listed in Figures 1-8 ( Figures 1-8 correspond to the drugs obtained in Examples 1-8, respectively, venlafaxine group and 20 (S)-origin The dosage forms of the panaxadiol group were the same.)
- the mice were administered by injection for four days, and then forced swimming experiments were performed. The swimming model lasts for 6 minutes and stops moving for 4 minutes after recording. The results are shown in Figure 1-8. ( 4 Conclusion
- the derivatives I and II can significantly shorten the swimming time in mice at different doses; and the dose is much lower than the positive control venlafaxine. At the same dose (0.75 mg/kg), the activity was significantly stronger than that of 20(S)-protopanaxadiol.
- the specific method is to stick the tail of the mouse 1 cm away from the tip with a tape and a 1 cm diameter PVC tube. Do not twist the mouse tail, then lift the PVC tube to make the mouse overhang. The head is 5 cm from the table. The mice were separated by a partition so that they did not interfere with each other. The time of each animal was observed to be immobile for 6 minutes (the immobility index was that all the animals except the breathing were not moving), and the mice were adapted for 1 or 2 minutes. , using the instrument to record the cumulative time of the mouse after 5 minutes, absolutely no time, struggle time, and keep the observation environment quiet and free from noise. The result is shown in Figure 9-16. ( 4 Conclusion
- the experimental method was as follows: After one week of adaptive feeding in rats, the CUMS procedure was started.
- CUMS experiment More than ten kinds of stress stimulating factors are administered to rats alternately every week, so that the rats can not predict the duration of each stress factor stimulation and the stimulation to be given next.
- Stimulating factors include: flash stimuli, noise stimuli, squirrel cage tilt; unfamiliar odor environment feeding, fasting, water ban.
- the venlafaxine at 20 mg/kg increased the sucrose intake of CUMS rats from the 4th week, and there was a statistically significant difference (PO.01) compared with the model group at week 5.
- the invention has structural modification of the original ginseng diol, and obtains various novel and unique compounds.
- the in vivo pharmacological experiments prove that these compounds have stronger anti-depressant activity and can be used as a preventive or therapeutic depression spirit.
- the active ingredient in disease drugs has a wide range of uses and development prospects.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020157022702A KR20150109456A (ko) | 2013-01-31 | 2014-01-26 | 프로토파녹사다이올 유도체 및 그의 제조방법과 용도 |
US14/764,543 US9475836B2 (en) | 2013-01-31 | 2014-01-26 | Protopanoxadiol derivative, preparation method thereof and application thereof |
JP2015555575A JP2016508489A (ja) | 2013-01-31 | 2014-01-26 | プロトパナキサジオール誘導体、その製造方法及びその応用 |
EP14746910.0A EP2952519A4 (en) | 2013-01-31 | 2014-01-26 | PROTOPANOXADIOL DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310038993.7A CN103965281B (zh) | 2013-01-31 | 2013-01-31 | 一种原人参二醇衍生物、其制备方法及其应用 |
CN201310038993.7 | 2013-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014117700A1 true WO2014117700A1 (zh) | 2014-08-07 |
Family
ID=51235329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/071500 WO2014117700A1 (zh) | 2013-01-31 | 2014-01-26 | 一种原人参二醇衍生物、其制备方法及其应用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9475836B2 (zh) |
EP (1) | EP2952519A4 (zh) |
JP (1) | JP2016508489A (zh) |
KR (1) | KR20150109456A (zh) |
CN (1) | CN103965281B (zh) |
WO (1) | WO2014117700A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020528080A (ja) * | 2018-05-15 | 2020-09-17 | 蘇州済爾生物医薬有限公司 | パナキサジオールサポニン誘導体、その調製方法および使用 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105985399B (zh) * | 2015-02-04 | 2018-08-24 | 中国药科大学 | (20S,24R/S)-环氧-12β,25-羟基-达玛烷-3β-胺衍生物的制备方法和用途 |
CN111704645B (zh) * | 2020-04-30 | 2021-12-07 | 烟台大学 | 戴斯马丁试剂在合成Ocotillol型皂苷衍生物关键中间体中的应用 |
CN116159101A (zh) * | 2020-06-24 | 2023-05-26 | 鲁南新时代生物技术有限公司 | 一种中药组合物及其制备方法与用途 |
CN114853839B (zh) * | 2022-06-13 | 2023-07-21 | 延边大学 | 一种人参二醇类化合物及其制备方法和医用用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1895256A (zh) * | 2006-06-09 | 2007-01-17 | 上海中药创新研究中心 | 20(s)-原人参二醇在制备抗抑郁药物中的应用 |
CN102018716A (zh) * | 2009-09-14 | 2011-04-20 | 王泽君 | 原人参三醇、原人参二醇在神经系统疾病的医疗应用 |
CN102731603A (zh) * | 2011-03-31 | 2012-10-17 | 上海兰蒂斯生物医药科技有限公司 | 人参二醇及20(r)-原人参二醇的制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1931177A (zh) * | 2006-09-21 | 2007-03-21 | 上海中药创新研究中心 | 20(s)-原人参二醇衍生物在制备抗抑郁药物中的应用 |
JPWO2008155998A1 (ja) * | 2007-06-21 | 2010-08-26 | 長瀬産業株式会社 | 抗不安抗うつ剤 |
CN102875628B (zh) * | 2012-10-30 | 2015-12-02 | 中国药科大学 | 具有抗菌活性的(20S,24S)-ocotillol型人参皂苷类衍生物、其制备方法及用途 |
CN102924556B (zh) * | 2012-11-05 | 2017-08-22 | 烟台大学 | 具有抗菌活性的(20S,24R)‑ocotillol型人参皂苷类衍生物、其制备方法及用途 |
-
2013
- 2013-01-31 CN CN201310038993.7A patent/CN103965281B/zh active Active
-
2014
- 2014-01-26 WO PCT/CN2014/071500 patent/WO2014117700A1/zh active Application Filing
- 2014-01-26 JP JP2015555575A patent/JP2016508489A/ja active Pending
- 2014-01-26 EP EP14746910.0A patent/EP2952519A4/en not_active Withdrawn
- 2014-01-26 US US14/764,543 patent/US9475836B2/en active Active
- 2014-01-26 KR KR1020157022702A patent/KR20150109456A/ko not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1895256A (zh) * | 2006-06-09 | 2007-01-17 | 上海中药创新研究中心 | 20(s)-原人参二醇在制备抗抑郁药物中的应用 |
CN102018716A (zh) * | 2009-09-14 | 2011-04-20 | 王泽君 | 原人参三醇、原人参二醇在神经系统疾病的医疗应用 |
CN102731603A (zh) * | 2011-03-31 | 2012-10-17 | 上海兰蒂斯生物医药科技有限公司 | 人参二醇及20(r)-原人参二醇的制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020528080A (ja) * | 2018-05-15 | 2020-09-17 | 蘇州済爾生物医薬有限公司 | パナキサジオールサポニン誘導体、その調製方法および使用 |
JP7083394B2 (ja) | 2018-05-15 | 2022-06-10 | 蘇州済爾生物医薬有限公司 | パナキサジオールサポニン誘導体、その調製方法および使用 |
Also Published As
Publication number | Publication date |
---|---|
US20150368289A1 (en) | 2015-12-24 |
KR20150109456A (ko) | 2015-10-01 |
JP2016508489A (ja) | 2016-03-22 |
CN103965281B (zh) | 2016-06-08 |
CN103965281A (zh) | 2014-08-06 |
US9475836B2 (en) | 2016-10-25 |
EP2952519A1 (en) | 2015-12-09 |
EP2952519A4 (en) | 2016-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7026152B2 (ja) | フェノール性trpv1アゴニストのプロドラッグ | |
WO2014117700A1 (zh) | 一种原人参二醇衍生物、其制备方法及其应用 | |
WO2013060258A1 (zh) | 伸筋草碱a-c、其制法和其药物组合物与用途 | |
EP3564253A1 (en) | Antidepressant compound and preparation method and application thereof | |
US20120252901A1 (en) | Agomelatine and pharmaceutical compositions thereof | |
JP6697808B2 (ja) | 感覚有毛細胞の死を防ぐまたは処置するための化合物と方法 | |
JP6126040B2 (ja) | ニコサミド(Nicousamide)化合物の五つの晶型、その製法やその薬物組合と用途 | |
CN102050755A (zh) | 阿戈美拉汀的新晶型及其制备方法 | |
CN108553456B (zh) | 苯甲酸及其衍生物的用途 | |
TW202019887A (zh) | 酚系trpv1促效劑之聚乙二醇化前藥 | |
CN106963766B (zh) | 一种氮杂螺酮类药物组合物及其制备方法 | |
CN103211823B (zh) | 20(s)-原人参二醇衍生物及20(s)-原人参三醇衍生物在制备抗抑郁药物中的用途 | |
WO2017074957A1 (en) | Oxysterols and hedgehog signaling | |
JP2013503908A (ja) | ニューロキニン2受容体活性に関連する障害または疾患を治療するための化合物 | |
WO2015000370A1 (zh) | 吡咯喹啉醌锂盐晶体及其制备方法和应用 | |
WO2014117699A1 (zh) | 原人参二醇衍生物、原人参三醇衍生物在制药中的应用 | |
CN115245511B (zh) | 一种小檗碱和水飞蓟宾形成的盐、其制备方法和应用 | |
CN117285458A (zh) | 一种无定型雷芬那辛及其制备方法 | |
CN106397412A (zh) | 5‑羟色胺受体激动剂及其制备方法和用途 | |
WO2023076997A1 (en) | Modified forms of ambroxol for therapeutic use | |
CN117180235A (zh) | 一种无定型雷芬那辛吸入制剂 | |
WO2023146842A1 (en) | C25 r and s isomers of aminosterols and methods of making and using the same | |
CN111135172A (zh) | 一种化合物治疗咽炎的新用途 | |
TW202325285A (zh) | 粉末製劑 | |
CN100367965C (zh) | 吉吡隆代谢物在制备改善哺乳动物不良心理状态的组合物上的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14746910 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015555575 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14764543 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014746910 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014746910 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20157022702 Country of ref document: KR Kind code of ref document: A |